Guardant360 (GH): חוב לטווח קצר להון

Guardant Health, Inc. (GH) relies on an impeccable reputation for developing precision blood tests for personalized therapy. A high barrier to entry is ensured by strict patent laws and costly certifications. Breakthrough developments in MRD and the SHIELD system are transforming diagnostics, while the company's pricing evolution on GURU.Markets, where the metric stands at 0.00, confirms these fundamental business successes.

This indicator calculates the ratio of short-term liabilities with maturities of up to one year to total equity, determining the company's level of dependence on operational refinancing. An increase in this ratio signals rising bankruptcy risks, which is particularly critical for Guardant Health, Inc. (GH) amid geopolitical isolation and the disruption of biomaterial logistics that hinder the global scaling of tests. By analyzing the change in short-term debt load relative to equity, an investor assesses the financial stability of the business.